1-May-2026
TipRanks (Fri, 1-May 9:50 PM ET)
Teleflex Names Jason Weidman as New CEO
TipRanks (Thu, 30-Apr 5:39 PM ET)
Medical device maker Teleflex appoints new CEO
Seeking Alpha News (Thu, 30-Apr 8:59 AM ET)
Teleflex Appoints Jason Weidman as President and CEO
Business Wire (Thu, 30-Apr 6:30 AM ET)
Teleflex Announces First Quarter 2026 Earnings Conference Call Information
Business Wire (Thu, 23-Apr 6:30 AM ET)
Teleflex Announces Governance Updates
Business Wire (Thu, 9-Apr 6:30 AM ET)
Irenic Comments on Teleflex's Announcement That It Is Open to Strategic Alternatives
Business Wire (Fri, 27-Mar 2:31 PM ET)
Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution
Business Wire (Fri, 27-Mar 12:57 PM ET)
Market Chameleon (Fri, 27-Mar 4:11 AM ET)
Business Wire (Fri, 27-Mar 7:30 AM ET)
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
Teleflex trades on the NYSE stock market under the symbol TFX.
As of May 1, 2026, TFX stock price declined to $121.77 with 772,735 million shares trading.
TFX has a beta of 0.80, meaning it tends to be less sensitive to market movements. TFX has a correlation of 0.10 to the broad based SPY ETF.
TFX has a market cap of $5.38 billion. This is considered a Mid Cap stock.
Last quarter Teleflex reported $569 million in Revenue and $1.93 earnings per share. This fell short of revenue expectation by $-349 million and missed earnings estimates by -$1.81.
In the last 3 years, TFX traded as high as $276.43 and as low as $100.18.
The top ETF exchange traded funds that TFX belongs to (by Net Assets): IJR, VTI, VB, VBR, VXF.
TFX has underperformed the market in the last year with a price return of -10.2% while the SPY ETF gained +31.3%. However, in the short term, TFX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.0% vs +4.4% return in SPY. But in the last 2 weeks, TFX shares have been beat by the market, returning -6.5% compared to an SPY return of +2.7%.
TFX support price is $120.51 and resistance is $127.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TFX shares will trade within this expected range on the day.